Natco Pharma FY26 Sustainability Report Highlights Key Operational Metrics and Targets
Natco Pharma Ltd · Others (Uncategorized) · 05 Sept 2026, 2:02 am
Natco Pharma FY26 Sustainability Report Highlights Key Operational Metrics and Targets Natco Pharma generated standalone turnover of ₹35,946 mn and net worth of ₹85,526 mn in FY25-26, with exports contributing 74%. R&D investments reached ₹4,086 mn (10.5% of total), while capital expenditure dedicated to environmental impact was ₹74.2 mn. Scope 1 and Scope 2 GHG emissions totaled 68,389 tCO2e, with an emission intensity of 1.677 tCO2e/₹ mn turnover. Renewable energy comprised 18.47% of total energy use, progressing toward a 35% target by 2035 and net-zero by 2050. Accounts payable stood at 160 days.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet · 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 · 14 Nov 2026
- Q2 FY27 Earnings Presentation · 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- Intimation of schedule of Concall · 13 Nov 2026
